ClinicalTrials.gg
CompletedNCT01851707ASPIRAUpdated Mar 17, 2021

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone

A Phase 2 interventional study of IPI-145 and Placebo in Rheumatoid Arthritis, sponsored by SecuraBio. Completed at 64 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.

Enrollment
129th of 284
322 · median 292
Started
2013
with 18 others
Phase 2
141 of 290
6 open now
Registered
144th of 290
by date

Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 129th largest by enrollment of the 284 interventional ones that give a count, is one of 19 that started in 2013, is one of 141 in phase 2, and was the 144th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Arthritis, Rheumatoid with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with active moderate-to-severe Rheumatoid Arthritis.

Read the detailed description

This Phase 2 study is designed to examine the efficacy and safety of multiple dose levels of IPI-145 in subjects with active moderate-to-severe Rheumatoid Arthritis receiving a background stable dose of methotrexate. The study will employ a randomized, double-blind, placebo-controlled, parallel design.

Approximately 316 adult subjects who meet all eligibility criteria at Screening will be randomized at Baseline in a 1:1:1:1 ratio to one of 4 dose groups.

All treatments will be administered twice a day (BID). After randomization, subjects will enter a 12-week Treatment Period, where study drug (IPI-145 or placebo) will be self-administered BID as an outpatient. During the Treatment Period, subjects will return to the clinic for efficacy and safety assessments every 2 weeks. Following Treatment Period completion at Week 12, subjects will enter a 3-week Follow-up Period which includes one clinic visit approximately 3 weeks after the last dose of study drug.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of Rheumatoid Arthritis for at least 6 months
  • Active disease, based on Screening clinical and laboratory criteria, despite taking methotrexate for at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Previous failure or inadequate response to >2 biologic disease-modifying anti-rheumatic drugs (DMARDs)
  • Concurrent DMARD treatment other than methotrexate, sulfasalazine, chloroquine, or hydroxychloroquine
  • Treatment with > 10 mg daily prednisone (or equivalent) or more than one non-steroidal anti-inflammatory drug
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    IPI-145, low dose BID

    Drug: IPI-145

  • Experimental
    IPI-145, medium dose BID

    Drug: IPI-145

  • Experimental
    IPI-145, high dose BID

    Drug: IPI-145

  • Placebo comparator
    Placebo BID

    Drug: Placebo

Interventions

  • 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

  • DrugPlacebo

    2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieve a 20% improvement in the American College of Rheumatology Criteria (ACR20) from Baseline to Week 12

    Time frame: Baseline (Day 1), Weeks 2, 4, 6, 8, 10 and 12

07

Study locations

64 sites
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Ruse, Bulgaria
  • Sofia, Bulgaria
  • Stara Zagora, Bulgaria
  • Targovishte, Bulgaria
  • Varna, Bulgaria
  • Medellin, Antioquia, Colombia
  • Bogota, Cundinamarca, Colombia
  • Bucaramanga, Santander, Colombia
  • Frankfurt, Germany
  • Halle, Germany
  • Budapest, Hungary
  • Kecskemet, Hungary
  • Mezokovesd, Hungary
  • Nyiregyhaza, Hungary
  • Veszprem, Hungary
  • Mexico City, Col Roam Sur, Mexico
  • Mexico City, Del Cuautemoc, Mexico
  • Leon, Guanajuato, Mexico
  • Guadalajara, Jalisco, Mexico
  • Madero, Mexico DF, Mexico
  • Morelia, Michoacan, Mexico
  • Monterrey, Nuevo Leon, Mexico
  • San Luis Potosi, San Luis Potosi, C.P., Mexico
  • Merida, Yucatan, Mexico
  • Mexico City, Mexico
  • Otahuhu, Auckland, New Zealand
  • Wellington, New Zealand
  • Grodzisk, Mazowiecki, Poland
  • Kraków, Okulickiego, Poland
  • Bialystok, Poland
  • Elblag, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Nadarzyn, Poland
  • Poznan, Poland
  • Skierniewice, Poland
  • Sosnowiec, Poland
  • Stalowa Wola, Poland
  • Starachowice, Poland
  • Wroclaw, Poland
  • Baia Mare, Romania
  • Braila, Romania
  • Bucharest, Romania
  • Oradea, Romania
  • Timisoara, Romania
  • Petrozavodsk, Karelia, Russian Federation
  • Ryazan, Ryazanskaya Oblast, Russian Federation
  • Moscow, Russian Federation
  • Orenburg, Russian Federation
  • Saratov, Russian Federation
  • St. Petersburg, Russian Federation
  • Vladimir, Russian Federation
  • Yaroslavl, Russian Federation
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Poltava, Ukraine
  • Ternopil, Ukraine
  • Zaporizhzhya, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Dec 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2013
First posted
May 10, 2013
Start
Apr 2013
Primary completionActual
Dec 2014
CompletionActual
Feb 2015
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01851707
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
May 10, 2013
Start date
Apr 2013
Primary completion
Dec 2014
Completion
Feb 2015
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion